Tango Therapeutics, Inc. (TNGX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Tango Therapeutics, Inc. (TNGX) Healthcare & Pipeline Overview

Tango Therapeutics, Inc. is a biotechnology company pioneering synthetic lethal approaches to cancer treatment. Specializing in small molecule inhibitors, its pipeline targets specific genetic vulnerabilities in tumors, including MTAP-deleted, BRCA1/2-mutant, and STK11-mutant cancers. The company leverages a strategic collaboration with Gilead Sciences to advance its innovative drug discovery and development efforts.

What Is the Investment Thesis for TNGX?

Tango Therapeutics, Inc. presents an investment thesis centered on its innovative synthetic lethality platform and a pipeline targeting genetically defined cancer populations with high unmet needs. The company's lead program, TNG908, a PRMT5 inhibitor for MTAP-deleted cancers, leverages a validated synthetic lethal interaction, representing a significant market opportunity given the prevalence of MTAP deletions in various solid tumors. Further pipeline assets, such as the USP1 inhibitor for BRCA1/2-mutant cancers and Target 3 for STK11-mutant cancers, diversify its therapeutic reach within precision oncology. The strategic collaboration with Gilead Sciences, Inc. provides substantial non-dilutive funding, clinical development expertise, and potential future commercialization support, significantly de-risking Tango's early-stage development efforts. With a market capitalization of $3.93B, the company's valuation reflects the potential of its platform and pipeline, despite a current profit margin of -188.2% typical for a clinical-stage biotechnology firm. The high gross margin of 97.3% indicates efficient R&D spending relative to its operational structure. Key catalysts include progression of TNG908 and other pipeline candidates through clinical trials, achievement of development milestones under the Gilead partnership, and potential data readouts that validate its synthetic lethal approach.

Based on FMP financials and quantitative analysis

TNGX Key Highlights

Market Capitalization: Tango Therapeutics maintains a market capitalization of $3.93B, reflecting investor valuation of its innovative synthetic lethality platform and early-stage oncology pipeline.

• Profit Margin: The company reported a profit margin of -188.2%, which is characteristic of a clinical-stage biotechnology company heavily investing in research and development without significant commercialized products.
• Gross Margin: Tango Therapeutics achieved a gross margin of 97.3%, indicating strong control over its direct costs, primarily related to its research operations, before accounting for broader operational expenses.
• Beta: With a Beta of 1.22, TNGX stock demonstrates higher volatility compared to the broader market, which is common for biotechnology companies whose valuations are often sensitive to clinical trial news and regulatory updates.
• Strategic Collaboration: The ongoing strategic collaboration with Gilead Sciences, Inc. is a critical operational highlight, providing significant financial support and validation for Tango's drug discovery and development efforts in oncology.

Who Are TNGX's Competitors?

TNGX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TNGX's Key Strengths?

Specialized synthetic lethality drug discovery platform with a focus on precision oncology.

• Diverse pipeline targeting genetically defined cancers (MTAP-deleted, BRCA1/2-mutant, STK11-mutant).
• Strategic collaboration with Gilead Sciences, providing significant funding and development support.
• Strong gross margin of 97.3% indicating efficient R&D cost management.
• Experienced leadership team overseeing 155 employees.

What Are TNGX's Weaknesses?

Negative profit margin of -188.2%, typical for a clinical-stage biotech, indicating reliance on external funding.

• Pipeline is in early to mid-stage clinical development, with no commercialized products yet.
• Significant capital requirements for ongoing research and clinical trials.
• High beta of 1.22 suggests stock price volatility, sensitive to clinical trial outcomes.

What Could Drive TNGX Stock Higher?

TNGX catalyst: Clinical data readouts for TNG908 in MTAP-deleted cancers, expected to provide further validation of its efficacy and safety profile.

• Progression of the USP1 inhibitor program into later-stage clinical trials for BRCA1/2-mutant cancers, signaling advancement in the pipeline.
• Achievement of research and development milestones under the strategic collaboration with Gilead Sciences, triggering potential milestone payments.
• Initiation of clinical trials for Target 3 in STK11-mutant cancers, expanding the company's clinical footprint.
• Expansion of the synthetic lethality platform, leading to the identification and nomination of new preclinical candidates.

What Are the Key Risks for TNGX?

Negative return on equity (-25.7%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or unexpected adverse events for TNG908 or other pipeline candidates, which could halt development and negatively impact valuation.
• Regulatory delays or non-approvals from health authorities (e.g., FDA, EMA) for any of Tango's drug candidates, extending timelines or preventing market entry.
• Significant cash burn due to extensive R&D expenses, necessitating future capital raises that could dilute existing shareholders.
• Intense competition in the oncology space, with other companies developing similar or superior therapies that could limit market share.
• Dependence on the strategic collaboration with Gilead Sciences for funding and development support; any changes to this partnership could impact operations.

What Are the Growth Opportunities for TNGX?

• Growth opportunity 1: Advancement of TNG908 for MTAP-deleted Cancers. TNG908, Tango's lead program, targets cancers with methylthioadenosine phosphorylase (MTAP) deletions, a genetic alteration found in approximately 10-15% of all human cancers, including non-small cell lung cancer, mesothelioma, and pancreatic cancer. The global market for oncology therapeutics is projected to reach over $300 billion by 2027, with targeted therapies forming a significant segment. Successful clinical development and regulatory approval of TNG908 could unlock a substantial market opportunity, addressing a clear unmet medical need. The timeline for this opportunity is tied to ongoing clinical trials and subsequent regulatory submissions, potentially yielding significant data readouts in the next 2-4 years.
• Growth opportunity 2: Development of USP1 Inhibitor for BRCA1/2-mutant Cancers. Tango's Ubiquitin-specific protease 1 (USP1) inhibitor program targets cancers with BRCA1 or BRCA2 mutations, which are prevalent in certain breast, ovarian, and prostate cancers. These mutations impair DNA repair, making cancer cells vulnerable to synthetic lethal approaches. The market for BRCA-mutated cancer therapies, including PARP inhibitors, is already well-established and growing, with an estimated value in the billions. A novel USP1 inhibitor could offer a differentiated therapeutic option, particularly for patients who have developed resistance to existing treatments. Clinical progress and positive data from this program over the next 3-5 years represent a significant growth driver.
• Growth opportunity 3: Progression of Target 3 for STK11-mutant Cancers. The company's Target 3 program focuses on STK11-mutant cancers, which are often aggressive and resistant to current therapies, particularly in non-small cell lung cancer. STK11 mutations are found in approximately 15-20% of lung adenocarcinomas, representing a distinct patient population with poor prognoses and limited treatment options. Developing an effective therapy for this subgroup could capture a critical niche within the vast lung cancer market, which is projected to exceed tens of billions annually. Initial clinical data and subsequent advancement of Target 3 over the next 4-6 years would be a key value inflection point.
• Growth opportunity 4: Expansion of the Strategic Collaboration with Gilead Sciences. The existing strategic collaboration with Gilead Sciences, Inc. provides a robust framework for discovering, developing, and commercializing multiple oncology therapies. This partnership not only provides significant funding and resources but also validates Tango's synthetic lethality platform and expertise. Future expansion of this collaboration, either through additional targets, increased funding, or successful progression of existing partnered programs into later-stage clinical trials, could substantially enhance Tango's financial stability and pipeline depth. The ongoing nature of this collaboration means its impact is continuous, with potential for milestone payments and increased scope over the next 5-10 years.
• Growth opportunity 5: Broadening the Synthetic Lethality Platform. Tango's core strength lies in its proprietary synthetic lethality platform, which enables the systematic identification of novel drug targets. Continued investment in this platform to discover new synthetic lethal pairs and expand its target pipeline beyond the current three clinical programs represents a long-term growth opportunity. The potential to generate a steady stream of innovative drug candidates for various cancer types could establish Tango as a leader in precision oncology. This foundational capability allows for continuous pipeline replenishment, with new targets potentially entering preclinical development within the next 2-3 years and clinical trials within 5-7 years, ensuring sustained growth beyond current assets.

What Threats Does TNGX Face?

• High risk of clinical trial failures, which can lead to significant delays or discontinuation of programs.
• Intense competition from other pharmaceutical and biotechnology companies developing oncology treatments.
• Regulatory hurdles and lengthy approval processes for novel drug candidates.
• Dependence on the success of its lead programs and the ongoing collaboration with Gilead Sciences.
• Potential for intellectual property challenges or expiration of key patents.

What Are TNGX's Competitive Advantages?

• Proprietary Synthetic Lethality Platform: Expertise in identifying and exploiting synthetic lethal interactions offers a unique approach to drug discovery.
• Targeted Pipeline Assets: Development of specific small molecule inhibitors for genetically defined cancer populations addresses unmet needs with precision.
• Strategic Collaboration with Gilead Sciences: A significant partnership providing financial resources, scientific validation, and potential commercialization infrastructure.
• Intellectual Property: Patents and proprietary knowledge surrounding its drug candidates and synthetic lethal targets create barriers to entry for competitors.
• Specialized Scientific Expertise: A team with deep knowledge in cancer biology, medicinal chemistry, and clinical development focused on precision oncology.

What Does TNGX Do?

Tango Therapeutics, Inc., founded in 2017 and headquartered in Cambridge, Massachusetts, is a clinical-stage biotechnology company dedicated to the discovery and development of novel precision medicines for cancer. The company's core strategy revolves around synthetic lethality, a therapeutic approach where the simultaneous inhibition of two genes or pathways leads to cell death, while inhibition of either alone is tolerated. This method allows Tango to target specific genetic vulnerabilities within cancer cells, aiming to develop highly selective and effective treatments with reduced toxicity to healthy tissues. At the forefront of Tango's pipeline is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5). TNG908 is being developed to treat cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions, a common genetic alteration found in various tumor types. Beyond TNG908, the company is advancing other promising programs, including an Ubiquitin-specific protease 1 (USP1) inhibitor designed for patients with BRCA1 or BRCA2-mutant cancers, which often exhibit deficiencies in DNA repair pathways. Additionally, Tango is developing Target 3, a novel therapeutic candidate aimed at STK11-mutant cancers, addressing another significant unmet medical need in oncology. A pivotal aspect of Tango Therapeutics' operational and financial strategy is its strategic collaboration with Gilead Sciences, Inc. This partnership encompasses the discovery, development, and potential commercialization of a broader pipeline of therapies for cancer patients, providing significant resources and validation for Tango's synthetic lethal platform. With a team of 155 employees, Tango Therapeutics continues to focus on translating its deep understanding of cancer biology into transformative medicines, positioning itself as a key player in the evolving landscape of precision oncology.

What Products and Services Does TNGX Offer?

• Discovers and develops small molecule drugs for cancer treatment.
• Utilizes a synthetic lethality approach to target specific genetic vulnerabilities in cancer cells.
• Advances TNG908, a PRMT5 inhibitor, for cancers with methylthioadenosine phosphorylase (MTAP) deletions.
• Develops a Ubiquitin-specific protease 1 (USP1) inhibitor for BRCA1 or BRCA2-mutant cancers.
• Researches Target 3 for the treatment of STK11-mutant cancers.
• Engages in a strategic collaboration with Gilead Sciences, Inc. for oncology drug discovery and commercialization.
• Focuses on precision oncology, aiming for highly selective and effective therapies.

How Does TNGX Make Money?

• Drug Discovery and Development: Invests in preclinical and clinical research to identify and advance novel oncology drug candidates.
• Strategic Partnerships: Generates revenue through collaboration agreements, such as the one with Gilead Sciences, which may include upfront payments, research funding, and milestone payments.
• Potential Future Commercialization: Aims to commercialize approved drugs, either independently or through partnerships, generating sales revenue.
• Intellectual Property Licensing: Protects its discoveries through patents and may license its technology or drug candidates to other pharmaceutical companies.

What Industry Does TNGX Operate In?

Tango Therapeutics operates within the highly specialized and competitive biotechnology industry, specifically focusing on oncology. The broader healthcare sector is experiencing a significant shift towards precision medicine, where treatments are tailored to a patient's genetic profile, and targeted therapies are increasingly preferred over traditional chemotherapy. Tango's synthetic lethality platform aligns directly with this trend, aiming to exploit specific genetic vulnerabilities in cancer cells. The oncology market is one of the largest and fastest-growing therapeutic areas, driven by an aging global population and advancements in understanding cancer biology. Competition is intense, with numerous pharmaceutical and biotech companies developing novel cancer treatments. Tango differentiates itself through its proprietary synthetic lethality expertise and a pipeline targeting specific, often difficult-to-treat, cancer mutations. The company's strategic partnership with Gilead Sciences also provides a competitive edge, offering substantial resources and a broader reach within the industry.

Who Are TNGX's Key Customers?

• Cancer patients who suffer from specific genetically defined tumors (e.g., MTAP-deleted, BRCA1/2-mutant, STK11-mutant cancers).
• Oncologists and healthcare providers seeking targeted and effective treatment options for their patients.
• Strategic pharmaceutical partners, such as Gilead Sciences, interested in co-developing and commercializing innovative oncology therapies.
• Research institutions and academic collaborators involved in advancing cancer biology and drug discovery.

Tango Therapeutics, Inc. Financial Trajectory

Tango Therapeutics, Inc. (TNGX) reported $0 in revenue for Q2 FY2026, based on the latest filing compared to the prior quarter. The company recorded a net loss of $55.3M, with diluted EPS of $-0.37. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, TNGX averaged $-0.22 in diluted EPS.

Company Profile

Tango Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Malte Peters. TNGX has traded publicly since 2020.

How Tango Therapeutics, Inc. Is Valued

Tango Therapeutics, Inc. carries a market capitalization of $3.93B, placing it in the mid-cap category. Analyst price targets span from $24.00 to $69.00, with a consensus of $45.91. At the current price of $24.13, that implies approximately 90% upside potential. Relative to its peer group, TNGX's quantitative score of 27/100 is below the peer average of 76/100.

Return on equity for Tango Therapeutics, Inc. stands at -25.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -11.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 50.82 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -3.7%, the inverse of the P/E and a quick read on earnings relative to price.

Tango Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 46.60 places it in the safe zone, indicating low near-term bankruptcy risk.

Tango Therapeutics, Inc. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 149.1% above estimates on average.

Over the past six months, Tango Therapeutics, Inc. insiders filed 29 SEC Form 4 transactions — 14 sales and 15 purchases. On net that is roughly 2K shares disposed (about $736K), a signal worth weighing alongside the fundamentals.

TNGX Financials

TNGX Latest News

TNGX Analyst Consensus

TNGX MoonshotScore

Tango Therapeutics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources